Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial
Open Access
- 1 November 2019
- journal article
- research article
- Published by Elsevier in European Urology Oncology
- Vol. 2 (6) , 677-684
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Novartis
- Astellas Pharma
- AbbVie
- Canada Millennium Scholarship Foundation
- Pfizer
- Janssen Research and Development
- Sanofi
- Bristol-Myers Squibb
- Eisai
- Pfizer
- Phycological Society of America
- Bayer
- Johnson & Johnson Innovative Medicine
- European Society for Medical Oncology
- Sanofi
- Johnson & Johnson Innovative Medicine
- Genentech
- Gilead Sciences
- AstraZeneca
- Astellas Pharma
- Amgen
This publication has 19 references indexed in Scilit:
- Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate CancerJAMA Oncology, 2018
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyEuropean Urology, 2017
- Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trialThe Lancet Oncology, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2014
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 2007
- Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16JNCI: Journal of the National Cancer Institute, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000